ROIV
Roivant Sciences Ltd.
NASDAQ · Healthcare · Biotechnology · GB
$36.62
−4.21%Price chart
Oct 7Oct 12Oct 15Oct 20Oct 23Oct 28Nov 2Nov 5
Key dataNov 5, 2026
Open$38.23
From 52W high−12.41%
Volume9.66M
Market cap$26.45B
P/E (TTM)—
P/S (TTM)3511.9x
Div yield—
Key dataNov 5, 2026
Open
$38.23
From 52W high
−12.41%
Volume
9.66M
Market cap
$26.45B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−81.5x
P/E (TTM)
—
RSI (14)
52.7
MomentumView details →
1D Return
−4.21%
YTD Return
+70.00%
SummaryUpdated Jun 1, 2026
Roivant Sciences Ltd. (NASDAQ:ROIV) is a biopharmaceutical and healthcare technology company founded in 2014 and headquartered in London, United Kingdom. The company went public in December 2020 and operates as a holding company that develops and commercializes innovative medicines across multiple therapeutic areas. Roivant has built a portfolio of subsidiary companies, each focused on specific drug development programs, and has successfully brought several products to market while maintaining a robust pipeline of clinical-stage assets targeting various diseases including autoimmune disorders, dermatological conditions, and rare diseases.
Similar companies
Latest newsMore news →
Roivant said it will seek expanded FDA approval for Lisraya in the first half of 2027.16d agoRoivant and its spinout Priovant reported that Lisraya was more effective than placebo in treating non-infectious uveitis in two Phase 3 trials involving 371 patients.16d agoImmunovant announced that it will report financial results for the fiscal second quarter ended September 30, 2026, on November 9, 2026, before the market opens.16d ago